Clinical features of primary and metastatic hepatic malignancies.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to S G Pappas.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Raloxifene is a member of a family of drugs known as selective estrogen receptor modulators (SERMs). Raloxifene is currently approved by the FDA for the prevention and treatment of osteoporosis in postmenopausal women. SERMs hold the potential to treat and prevent breast cancer, osteoporosis and coronary heart disease. Ongoing clinical trials are in place to address the role of raloxifene and SERMs in each of these areas. We review the pharmacology, clinical utility, safety and tolerability of raloxifene and speculate on what the future holds for SERMs and their use in breast cancer.
Explore the source record for details and available documents.